CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

365

Enrollment

INDUSTRY

Sponsor class

Stopped primary endpoint missed

Conditions

Moderate to Severe Allergic Asthma

Interventions

BIOLOGICAL: CYT003
BIOLOGICAL: Placebo

Sponsor

Cytos Biotechnology AG